Navigation Links
GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients
Date:7/13/2009

ARLINGTON, Va., July 13 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on the Senate HELP Committee's vote on biogenerics legislation.

"While we are extremely disappointed that the Committee action could result in patients having little or no access to affordable biogenerics, we will continue to fight in the House to ensure that a true balance is achieved between innovation and competition. It is surprising that in the wake of the recent Federal Trade Commission report explicitly stating that 12 years of exclusivity would discourage innovation, the HELP Committee voted in favor of profits over patients. This unprecedented action strikes a huge blow to consumers at a time when many Americans are struggling to pay for the medicines they need.

"With generics saving the health care system $734 billion in the last decade, the House must now act to ensure that additional savings can be achieved by rejecting unnecessary and excessive years of market exclusivity for biopharmaceuticals. Over the last two years, we have dispelled the myths on the safety and efficacy of biogenerics that brand PhRMA and BIO tried to make to keep biogenerics from getting to consumers. It is now time to dispel the myth that double-digit years of exclusivity are needed to spark innovation. The White House already has the FDA working on creating a pathway and it has firmly stated that seven years of exclusivity is a good compromise. We must follow the course of the White House and Chairman Waxman and ensure that patients can truly access lifesaving biogeneric medicines in a timely manner.

"We hope that when the House Energy and Commerce Committee acts it follows the lead of its Chairman in approving a market exclusivity period that puts patients first. History has shown that a balance be
'/>"/>

SOURCE Generic Pharmaceutical Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
3. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
4. International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive
5. Kaiser Permanente CEO Calls for Connected Health Care
6. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
7. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
8. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
9. Bauer Calls Taxpayer-Funded Embryonic Stem Cell Research A Tragedy
10. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
11. Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... Meeting of Shareholders to be Reconvened on May 29, ... Therapeutics,Corporation (Nasdaq: UTHR ) (the Company) held its ... 2008. The Company,s,shareholders voted to approve the election of ... directors with terms expiring in 2011. The,Company,s shareholders also ...
... IRVINE, Calif., May 1 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, will host ... 2008 beginning at 10:00 a.m. PT (1:00 pm,ET) ... A live webcast of the meeting will be ...
Cached Biology Technology:HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 2United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 3Edwards Lifesciences to Webcast Annual Stockholders Meeting 2
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... team of neuroengineers based at Brown University has developed ... of relaying real-time broadband signals from up to 100 ... novel low-power device, described in the Journal of ... models for more than year, a first in the ...
... long-term consequences of childhood obesity are well documented, some ... more time to the 3 Rs in educationreading, writing, ... leaving out an important fourth Raerobicscould actually be counterproductive ... for publication in The Journal of Pediatrics ...
... at Wake Forest Baptist Medical Center and colleagues have ... bone marrow that have the natural ability to migrate ... potential to restore healthy tissue in patients with inflammatory ... have IBD, which is characterized by frequent diarrhea and ...
Cached Biology News:Brown unveils novel wireless brain sensor 2Brown unveils novel wireless brain sensor 3Brown unveils novel wireless brain sensor 4Reading, writing, arithmetic, and aerobics -- Evaluating the new 'R' in academic performance 2Research supports promise of cell therapy for bowel disease 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: